Evidence map›Paper›PMID 39553979›Full record

ArticlebioRxiv : the preprint server for biology2024

A vaccine antigen central in influenza A(H5) virus antigenic space confers subtype-wide immunity.

Adinda Kok, Samuel H Wilks, Sina Tureli, Sarah L James, Theo M Bestebroer, David F Burke, Mathis Funk, Stefan van der Vliet, Monique I Spronken, Willemijn F Rijnink and 9 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Adinda KokDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
Samuel H WilksCenter for Pathogen Evolution, University of Cambridge; Cambridge, United Kingdom.
Sina TureliCenter for Pathogen Evolution, University of Cambridge; Cambridge, United Kingdom.
Sarah L JamesCenter for Pathogen Evolution, University of Cambridge; Cambridge, United Kingdom.
Theo M BestebroerDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
David F BurkeCenter for Pathogen Evolution, University of Cambridge; Cambridge, United Kingdom.
Mathis FunkDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
Stefan van der VlietDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
Monique I SpronkenDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
Willemijn F RijninkDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
David PattinsonDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
Dennis de MeulderDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
Miruna E RosuDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
Pascal LexmondDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
Judith M A van den BrandDivision of Pathology, Faculty of Veterinary Medicine, Utrecht University; Utrecht, the Netherlands.
Sander HerfstDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.ORCID 0000-0001-9866-8903
Derek J SmithCenter for Pathogen Evolution, University of Cambridge; Cambridge, United Kingdom.
Ron A M FouchierDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.
Mathilde RichardDepartment of Viroscience, Erasmus University Medical Center; Rotterdam, The Netherlands.

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
NIAID NIH HHS 75N93021C00014NIAID NIH HHS HHSN272201400008C
6 · The paper itself

Abstract

Highly pathogenic avian influenza A(H5) viruses globally impact wild and domestic birds, and mammals, including humans, underscoring their pandemic potential. The antigenic evolution of the A(H5) hemagglutinin (HA) poses challenges for pandemic preparedness and vaccine design. Here, the global antigenic evolution of the A(H5) HA was captured in a high-resolution antigenic map. The map was used to engineer immunogenic and antigenically central vaccine HA antigens, eliciting antibody responses that broadly cover the A(H5) antigenic space. In ferrets, a central antigen protected as well as homologous vaccines against heterologous infection with two antigenically distinct viruses. This work showcases the rational design of subtype-wide influenza A(H5) pre-pandemic vaccines and demonstrates the value of antigenic maps for the evaluation of vaccine-induced immune responses through antibody profiles.

Identifiers

PMID39553979
PMCPMC11566024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.